Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.

The outdoor-goods retailer is emerging from a rough patch, and its shares are cheap. Look for the stock to bounce back in 2025.

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff plans, then bounced back big once he said he would pause expanded tariffs ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, ...

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ETFs? The ...

A recent selloff of Neurocrine Biosciences stock feels unwarranted and may have created a contrarian buy opportunity. Learn ...

Designed to provide broad exposure to the Large Cap Growth segment of the US equity market, the First Trust NASDAQ-100 Ex-Technology Sector ETF (QQXT) is a passively managed exchange traded fund ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Aristotle Atlantic’s Core Equity Composite posted a total return of -5.90% gross of fees (-5.99% net of fees). Read more here.

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...